Immunovant Inc (IMVT)

NASDAQ
Currency in USD
15.80
-0.06(-0.38%)
Closed·
After Hours
15.800.00(0.00%)
·
IMVT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.4416.04
52 wk Range
12.7234.47
Key Statistics
Edit
Prev. Close
15.86
Open
16.04
Day's Range
15.44-16.04
52 wk Range
12.72-34.47
Volume
1.91M
Average Vol. (3m)
1.64M
1-Year Change
-42.17%
Book Value / Share
4.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.38
Upside
+174.59%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Immunovant Inc News & Analysis

Show more

Immunovant Inc Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant Inc SWOT Analysis


Strategic Expansion
Learn about Immunovant's ambitious plan to target 10 indications by 2026, potentially diversifying risk and expanding market reach
Financial Outlook
Analysts set price targets ranging from $36 to $58, suggesting significant upside potential despite recent stock price decline
Market Opportunity
Explore the substantial market for Graves' disease treatment, with an estimated 20,000 high-need patients diagnosed annually in the US
Promising Pipeline
Immunovant's anti-FcRn therapy shows potential in treating Graves' disease and other autoimmune conditions, with impressive IgG reduction capabilities
Read full SWOT analysis

Compare IMVT to Peers and Sector

Metrics to compare
IMVT
Peers
Sector
Relationship
P/E Ratio
−6.5x−4.7x−0.5x
PEG Ratio
0.140.080.00
Price / Book
3.8x5.9x2.6x
Price / LTM Sales
-9.2x3.0x
Upside (Analyst Target)
184.8%195.9%52.6%
Fair Value Upside
Unlock14.5%8.7%Unlock

Analyst Ratings

12 Buy
3 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.38
(+174.59% Upside)

Earnings

Latest Release
May 29, 2025
EPS / Forecast
-0.64 / -0.712
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMVT Income Statement

People Also Watch

132.46
KRYS
+0.28%
2.70
RCKT
-4.59%
102.68
INSM
+3.24%
34.41
AGIO
-3.07%
0.720
IMUX
-3.48%

FAQ

What Is the Immunovant (IMVT) Stock Price Today?

The Immunovant stock price today is 15.80

What Stock Exchange Does Immunovant Trade On?

Immunovant is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immunovant?

The stock symbol for Immunovant is "IMVT."

What Is the Immunovant Market Cap?

As of today, Immunovant market cap is 2.70B.

What Is Immunovant's Earnings Per Share (TTM)?

The Immunovant EPS (TTM) is -2.73.

When Is the Next Immunovant Earnings Date?

Immunovant will release its next earnings report on Aug 06, 2025.

From a Technical Analysis Perspective, Is IMVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Immunovant Stock Split?

Immunovant has split 0 times.

How Many Employees Does Immunovant Have?

Immunovant has 362 employees.

What is the current trading status of Immunovant (IMVT)?

As of Jun 23, 2025, Immunovant (IMVT) is trading at a price of 15.80, with a previous close of 15.86. The stock has fluctuated within a day range of 15.44 to 16.04, while its 52-week range spans from 12.72 to 34.47.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.